<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612232</url>
  </required_header>
  <id_info>
    <org_study_id>CaboACC</org_study_id>
    <nct_id>NCT03612232</nct_id>
  </id_info>
  <brief_title>Cabozantinib in Advanced Adrenocortical Carcinoma</brief_title>
  <acronym>CaboACC</acronym>
  <official_title>Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adrenocortical carcinoma is an orphan malignant disease that has a dismal prognosis in
      advanced stages. Mitotane is the only approved treatment but is limited by severe toxicity.
      Efficacy of mitotane is unsatisfactory with an objective response rate of ≈20% in monotherapy
      in selected patients (Megerle et al. JCEM 2018). Cytotoxic chemotherapy with etoposide,
      doxorubin and cisplatin (EDP) or streptozotocin in (Sz) addition to mitotane (Fassnacht et
      al., N Engl J Med 2012) succeeded in a progression-free survival of 5.6 months and 2.2
      months, respectively in patients with advanced ACC. Objective response rates were 23 and 9%.
      EDP plus mitotane is therefore considered as standard treatment of ACC.

      There is a need for more effective and less toxic treatments of ACC.

      Results by Phan et al (Cancer Research, 2015) demonstrated expression of c-MET and its ligand
      HGF in ACC and provide a rationale to therapeutically target c-MET in ACC. In a case series
      of 7 patients with advanced ACC refractory to a median of 4 (2-8) prior lines of therapy,
      single agent treatment with cabozantinib as an off label therapy resulted in two partial
      responses and two additional cases of long-term disease stabilization (Wendler et al, ENDO
      2018).

      This is a prospective, non-randomized, open-label, single arm, single center phase II study
      to investigate the efficacy of oral continuous cabozantinib in adult patients with
      histologically confirmed adrenocortical carcinoma that is locally advanced or metastatic and
      who were refractory to or declined standard treatment. In patients previously on mitotane,
      mitotane administration must have been discontinued 28 days prior to study treatment and a
      mitotane serum concentration &lt;2 mg/l has been documented.

      Response rate will be calculated as the proportion of patients with progression-free survival
      at 4 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival at 4 months</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best percentage change in size of target lesions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment emergent adverse events (CTC-AE 4.03)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life by EORTC QLQ-C30</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral cabozantinib as tablets continuously (60 mg single dose, tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib-s-malate</intervention_name>
    <description>oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed adrenocortical carcinoma that is locally advanced or
             metastatic who were refractory to or declined standard treatment.

          -  mitotane administration must have been discontinued 28 days prior to study treatment
             and a mitotane serum concentration &lt;2 mg/l must be documented.

          -  measurable disease as defined by the Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          -  no major bone marrow and organ dysfunction

        Exclusion Criteria:

          -  uncontrolled hypertension

          -  thromboembolic event 6 months prior to treatment initiation

          -  tumor manifestation with concern of fistula formation

          -  QT-interval of &gt; 500 ms in ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Kroiss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Kroiss, MD, PhD</last_name>
    <phone>+4993120139740</phone>
    <email>Kroiss_M@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Fassnacht, MD</last_name>
    <phone>+49931201-39200</phone>
    <email>Fassnacht_M@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Kroiss, MD, PhD</last_name>
      <phone>+4993120139740</phone>
      <email>Kroiss_M@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Fassnacht, MD</last_name>
      <phone>+4993120139200</phone>
      <email>Fassnacht_M@ukw.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://ukw.de</url>
    <description>Wuerzburg University Hospital</description>
  </link>
  <reference>
    <citation>Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015 Oct 1;75(19):4131-42. doi: 10.1158/0008-5472.CAN-14-3707. Epub 2015 Aug 17.</citation>
    <PMID>26282167</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenal cancer</keyword>
  <keyword>adrenal cortex neoplasm</keyword>
  <keyword>adrenal cortical carcinoma</keyword>
  <keyword>cabozantinib</keyword>
  <keyword>c-MET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

